TrialThe Lancet. Global health2025

Durability of immunogenicity at 5 years after a single dose of human papillomavirus vaccine compared with two doses in Tanzanian girls aged 9-14 years: results of the long-term extension of the DoRIS randomised trial.

Deborah Watson-Jones et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.